<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628379</url>
  </required_header>
  <id_info>
    <org_study_id>RAP-CLT-15-010</org_study_id>
    <nct_id>NCT02628379</nct_id>
  </id_info>
  <brief_title>Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary</brief_title>
  <official_title>A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stormont-Vail Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jefferson Medical College of Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sparrow Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer &amp; Hematology Centers of Western Michigan (CHCWM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Luke's University Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solano Hematology Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Horizon Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Blood and Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lancaster Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Maryland Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valley Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cape Fear Valley Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-County Hematology Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hematology &amp; Oncology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Broome Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orchard Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ashland Bellefonte Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tennessee Cancer Specialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Hematology Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Good Samaritan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zangmeister Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Watson clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Hematology Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Westchester Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peter MacCallum Cancer Center Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the current study is to determine whether Foundation Medicine's next generation
      sequencing assay, called FoundationOne, will provide information that allows physicians to
      make treatment decisions using targeted therapies in clinical trials or FDA approved
      therapies, including &quot;off-label&quot; agents, that result in superior OS compared to historical
      outcomes for standard CUP therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of CUP patients who receive matched targeted therapy.</measure>
    <time_frame>Baseline visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in CUP patients receiving matched targeted therapy based on FoundationOne versus internal control CUP patients not receiving FoundationOne-directed therapy</measure>
    <time_frame>Every three months until death, [20 months]</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neoplasms, Unknown Primary</condition>
  <condition>CUP</condition>
  <condition>Metastatic Disease</condition>
  <condition>Poorly Differentiated Adenocarcinoma</condition>
  <condition>Poorly Differentiated Carcinoma</condition>
  <condition>Squamous Carcinoma Poorly Differentiated</condition>
  <arm_group>
    <arm_group_label>Class 1, 2, or 3 alterations, with targeted therapy</arm_group_label>
    <description>Patients put on targeted therapies matched to specific genomic alterations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Site-specific therapy determined by tissue of origin testing</arm_group_label>
    <description>Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empiric CUP therapy</arm_group_label>
    <description>Patients put on empiric treatment at physician discretion</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed and previously treated patients with CUP.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a histologically or cytologically confirmed diagnosis of metastatic or
             advanced unresectable cancer of unknown primary including adenocarcinoma, poorly
             differentiated adenocarcinoma, poorly differentiated carcinoma, or squamous carcinoma.

          2. To be categorized as CUP, the following clinical evaluations must have been performed
             without identification of an anatomic primary site: medical history, physical
             examination, chemistry profile, blood counts, serum PSA (men), CT scans of
             chest/abdomen/pelvis, specific evaluation of symptomatic areas.

          3. Sufficient Formalin Fixed Paraffin Embedded tissue from cancer of study will allow
             previously completed profiling panels other than for treatment assignment; however,
             FoundationOne profiling is required as part of this study. Adequate tumor tissue must
             remain, in the estimate of the consenting physician, to confirm genomic alterations in
             enrolled patients. Previous unknown primary available for FoundationOne testing.
             (Note: This FoundationOneÂ® profiling is also allowed and is not required to be
             FoundationOne repeated.) (see Appendix A and Appendix B)

          4. First and second line patients enrolling in this study must have an Eastern
             Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2. Third line
             patients enrolling in this study must have an ECOG Performance Status score of 0 to 1
             (Appendix C).

          5. Patients must have measurable or evaluable disease per Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1 (Appendix D).

          6. Age greater than or equal to 18 years.

          7. Patients are considered potential candidates for treatment with targeted therapy.

          8. Willingness and ability to comply with study and follow-up procedures.

          9. Ability to understand the nature of this study and give written informed consent.

         10. The presence of other active cancers is not allowed, unless indolent and not requiring
             therapy. Patients with early stage cancer who have received definitive local treatment
             and are considered unlikely to recur are eligible. All patients with previously
             treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with
             history of non-melanoma skin cancer.

        Exclusion Criteria:

          1. Patients who have received three or more lines of systemic therapy for cancer of
             unknown primary.

          2. Patients who have previously received matched targeted therapy for the same Class 1
             alteration (see Table 1) or the same drug.

          3. Patients with treatable CUP syndrome, including the following:

               -  extragonadal germ cell syndrome

               -  neuroendocrine carcinoma

               -  adenocarcinoma isolated to axillary lymph nodes (women)

               -  peritoneal carcinomatosis (women)

               -  squamous cell carcinoma limited to cervical, supraclavicular, or inguinal lymph
                  nodes

               -  single resectable metastasis

          4. Previously untreated brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if therapy was completed at least 2 weeks prior to
             study entry and there is no evidence of central nervous system disease progression,
             mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.
             Enzyme-inducing anticonvulsants are contraindicated.

          5. Pregnant or lactating.

          6. Psychological, familial, sociologic, or geographic conditions that do not permit
             compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Foundation Medicine, Inc</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683. Epub 2015 Jan 7.</citation>
    <PMID>25567908</PMID>
  </reference>
  <reference>
    <citation>Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 2011 Oct;136(4):527-39. doi: 10.1309/AJCPR1SVT1VHUGXW. Review.</citation>
    <PMID>21917674</PMID>
  </reference>
  <reference>
    <citation>Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023-31. doi: 10.1038/nbt.2696. Epub 2013 Oct 20.</citation>
    <PMID>24142049</PMID>
  </reference>
  <reference>
    <citation>Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.</citation>
    <PMID>24797823</PMID>
  </reference>
  <reference>
    <citation>Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15;18(22):6373-83. doi: 10.1158/1078-0432.CCR-12-1627. Epub 2012 Sep 10.</citation>
    <PMID>22966018</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin--diagnosis and treatment. Nat Rev Clin Oncol. 2011 Nov 1;8(12):701-10. doi: 10.1038/nrclinonc.2011.158. Review.</citation>
    <PMID>22048624</PMID>
  </reference>
  <reference>
    <citation>Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012 Apr 14;379(9824):1428-35. doi: 10.1016/S0140-6736(11)61178-1. Epub 2012 Mar 12. Review.</citation>
    <PMID>22414598</PMID>
  </reference>
  <reference>
    <citation>Stella GM, Senetta R, Cassenti A, Ronco M, Cassoni P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med. 2012 Jan 24;10:12. doi: 10.1186/1479-5876-10-12. Review.</citation>
    <PMID>22272606</PMID>
  </reference>
  <reference>
    <citation>Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May 1;32(13):1317-23. doi: 10.1200/JCO.2013.52.4298. Epub 2014 Mar 24.</citation>
    <PMID>24663044</PMID>
  </reference>
  <reference>
    <citation>Varadhachary GR, Raber MN. Carcinoma of unknown primary site. N Engl J Med. 2014 Nov 20;371(21):2040. doi: 10.1056/NEJMc1411384.</citation>
    <PMID>25409386</PMID>
  </reference>
  <reference>
    <citation>Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev. 2013 Nov;39(7):701-8. doi: 10.1016/j.ctrv.2013.03.001. Epub 2013 Apr 6. Review.</citation>
    <PMID>23566573</PMID>
  </reference>
  <reference>
    <citation>Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.</citation>
    <PMID>23032625</PMID>
  </reference>
  <reference>
    <citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.</citation>
    <PMID>7165009</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomic Testing</keyword>
  <keyword>Cancer of Unknown Primary</keyword>
  <keyword>CUP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

